This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Curti, B. D. Articles by Longo, D. L. Search for Related Content PubMed PubMed Citation Articles by Curti, B. D. Articles by Longo, D. L.

Interstitial Pressure of Subcutaneous Nodules in Melanoma and Lymphoma Patients: Changes during Treatment¹

Biological Response Modifiers Program, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick 21701 [B. D. C., J. E. J., J. W. S.II, D. L. L.]; Clinical Services Program [W. J. U.], Program Resources, Inc./Dyn Corp., and Data Management Services, Inc. [W. G. A.], National Cancer Institute-Frederick Cancer Research and Development Center, Frederick 21702; and Frederick Memorial Hospital, Frederick 21701 [K. M.] Maryland

Interstitial pressure (IP) is a physiological variable that may have its greatest influence on the transport of high-molecular-weight therapeutic agents. IP in tumor nodules was measured in patients with metastatic melanoma or non-Hodgkin's lymphoma to determine the influence of this physiological variable on treatment outcome. The wick-in-needle technique was used to measure IP at time points before and after treatment with a variety of immunotherapy and chemotherapy regimens. Selected patients had IP measurements during chemotherapy or immunotherapy infusions. Ultrasound or computed tomography was used to evaluate the size of the studied lesions and their relationship to normal structures. The mean baseline IP in melanoma nodules (n = 22) and lymphoma nodules (n = 7) was 29.8 and 4.7 mm Hg, respectively (P = 0.013 for the difference between tumor types). In a subset of melanoma nodules for which IP had been measured before and after treatment, the IP increased significantly over time for nonresponding melanoma lesions from a baseline of 24.4 to 53.9 mm Hg after treatment (P = 0.005) and decreased in melanoma lesions that responded to treatment where the mean baseline and post-treatment IPs were 12.2 and 0 mm Hg, respectively (P = 0.001 for the difference in IP profiles between responding and nonresponding lesions). Six of seven lymphoma nodules responded completely to chemotherapy or radiation. The single nodule that did not respond had a baseline IP of 1 mm Hg that increased to 30 mm Hg after treatment. Tumor IP differs significantly between melanoma and non-Hodgkin's lymphoma. The changes in IP over time differ significantly between responding and non-responding melanoma lesions. IP that increases during treatment appears to be associated with tumor progression in these tumor types.

¹ The contents of this publication do not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

² To whom requests for reprints should be addressed, at Biological Response Modifiers Program, Division of Cancer Treatment, National Cancer Institute-Frederick Cancer Research and Development Center, 501 W. Seventh Street, Suite 3, Frederick, MD 21701.

Received 2/10/93. Accepted 4/ 1/93.

This article has been cited by other articles:

				O. Tredan, C. M. Galmarini, K. Patel, and I. F. Tannock Drug Resistance and the Solid Tumor Microenvironment J Natl Cancer Inst, October 3, 2007; 99(19): 1441 - 1454. [Abstract] [Full Text] [PDF]

				K. Hayashi, P. Jiang, K. Yamauchi, N. Yamamoto, H. Tsuchiya, K. Tomita, A.R. Moossa, M. Bouvet, and R. M. Hoffman Real-time Imaging of Tumor-Cell Shedding and Trafficking in Lymphatic Channels Cancer Res., September 1, 2007; 67(17): 8223 - 8228. [Abstract] [Full Text] [PDF]

				A. Eichten, W. C. Hyun, and L. M. Coussens Distinctive Features of Angiogenesis and Lymphangiogenesis Determine Their Functionality during De novo Tumor Development Cancer Res., June 1, 2007; 67(11): 5211 - 5220. [Abstract] [Full Text] [PDF]

				J. V. Skliarenko, S. J. Lunt, M. L. Gordon, A. Vitkin, M. Milosevic, and R. P. Hill Effects of the Vascular Disrupting Agent ZD6126 on Interstitial Fluid Pressure and Cell Survival in Tumors Cancer Res., February 15, 2006; 66(4): 2074 - 2080. [Abstract] [Full Text] [PDF]

				R. Cairns, I. Papandreou, and N. Denko Overcoming Physiologic Barriers to Cancer Treatment by Molecularly Targeting the Tumor Microenvironment Mol. Cancer Res., February 1, 2006; 4(2): 61 - 70. [Abstract] [Full Text] [PDF]

				K. Pietras, K. Rubin, T. Sjoblom, E. Buchdunger, M. Sjoquist, C.-H. Heldin, and A. Ostman Inhibition of PDGF Receptor Signaling in Tumor Stroma Enhances Antitumor Effect of Chemotherapy Cancer Res., October 1, 2002; 62(19): 5476 - 5484. [Abstract] [Full Text] [PDF]

				E. K. Rofstad, S. H. Tunheim, B. Mathiesen, B. A. Graff, E. F. Halsor, K. Nilsen, and K. Galappathi Pulmonary and Lymph Node Metastasis Is Associated with Primary Tumor Interstitial Fluid Pressure in Human Melanoma Xenografts Cancer Res., February 1, 2002; 62(3): 661 - 664. [Abstract] [Full Text] [PDF]

				M. Milosevic, A. Fyles, D. Hedley, M. Pintilie, W. Levin, L. Manchul, and R. Hill Interstitial Fluid Pressure Predicts Survival in Patients with Cervix Cancer Independent of Clinical Prognostic Factors and Tumor Oxygen Measurements Cancer Res., September 1, 2001; 61(17): 6400 - 6405. [Abstract] [Full Text] [PDF]

				G. Griffon-Etienne, Y. Boucher, C. Brekken, H. D. Suit, and R. K. Jain Taxane-induced Apoptosis Decompresses Blood Vessels and Lowers Interstitial Fluid Pressure in Solid Tumors: Clinical Implications Cancer Res., August 1, 1999; 59(15): 3776 - 3782. [Abstract] [Full Text] [PDF]